From Financial Modeling Prep: 2025-02-26 07:00:04

Insmed Incorporated is a biopharmaceutical company focusing on therapies for rare diseases. With an ROIC of -46.16% and a WACC of 9.98%, its capital utilization efficiency is concerning. Compared to competitors like Amicus Therapeutics, Cytokinetics, PTC Therapeutics, Ultragenyx Pharmaceutical, and Halozyme Therapeutics, only Halozyme shows strong capital efficiency with a positive ROIC of 22.84%.



Read more at Financial Modeling Prep:: Insmed Incorporated’s Financial Performance in the…